ReviewJournal of inflammation research2026
Bidirectional Crosstalk Between Intestinal Epithelium and Immune Microenvironment in Inflammatory Bowel Disease: Mechanisms and Therapeutic Implications.
Review in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Tumor Suppressor CADM1 Protects Against Colitis in Inflammatory Bowel Disease Through Enhancing Epithelial Regeneration.International journal of molecular sciences · 2026Article
- From Chronic Inflammation to Cancer: The Role of Trained Immunity in IBD-Associated Colorectal Carcinogenesis.Medical sciences (Basel, Switzerland) · 2026Review
- From Conventional Therapy to Precision Medicine in Inflammatory Bowel Disease: A State-of-the-Art Review.Biomedicines · 2026Review
- Stem Cell-Derived Organoids for Cancer Therapy: Precision Medicine and Drug Selection.International journal of molecular sciences · 2026Review
- Mechanisms and therapeutic prospects of DNA methylation-mucosal innate immunity crosstalk in inflammatory bowel disease.Frontiers in immunology · 2026Review
- The hallmarks of host-microbiome decoupling.Frontiers in microbiology · 2026Review
- Gut microbiota-host adaptive immune interactions in type 2 diabetes mellitus: mechanisms, disease progression, and microbiota-based therapeutic strategies.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD), encompassing Crohn's disease and ulcerative colitis, is characterized by chronic mucosal inflammation driven by dysregulated interactions between intestinal epithelial cells (IECs) and immune components. This review systematically explores the dynamic interplay between epithelial barrier integrity and immune-microenvironmental regulation in IBD pathogenesis. We highlight the dual roles of innate immunity (neutrophils, macrophages, dendritic cells, and innate lymphoid cells) and adaptive immunity (Th1, Th17, and Treg cells) in orchestrating inflammatory cascades and mucosal repair. It also describes the interaction between microbial metabolites and the intestinal microenvironment.Key mechanisms include neutrophil extracellular trap (NET)-mediated epithelial damage, macrophage polarization modulated by ROS/NOX4 signaling, and IL-22/STAT3-driven epithelial regeneration. Additionally, we dissect the Wnt/β-catenin and bile acid-TGR5 (Takeda G-protein-coupled receptor 5) pathways in intestinal stem cell renewal. Emerging therapeutic strategies targeting epithelial-immune axes, such as anti-IL-23/IL-17 biologics and MSC-derived exosomes, are critically evaluated. By integrating recent advances in single-cell omics and preclinical models, this review underscores the necessity of precision medicine approaches to restore immune-epithelial homeostasis. This paper also introduces the current application of organoids-a novel emerging technology-in experimental research.Future research should prioritize spatial-temporal mapping of cellular interactions and leverage organoids to advance translational validation of dual-target therapies to bridge mechanistic insights into clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.